NEW YORK, June 2, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced completion of enrollment of the PICASSO 3 trial, an international, randomized, double-blind, placebo-controlled Phase 3 clinical study of palifosfamide in combination with doxorubicin, versus doxorubicin alone, for the treatment of metastatic soft tissue sarcoma (STS) in the front-line setting. Doxorubicin is the current standard of care for the treatment of STS in the front-line setting.
